Federal court blocks mailing of mifepristone
A federal appeals court ruled that mifepristone, the abortion pill, can only be distributed in person at clinics, overturning FDA regulations that permitted mail delivery. The decision, supported by a Trump-appointed judge, aligns with Louisiana's argument that mailing the drug undermines its total abortion ban. The ruling is expected to be appealed to the Supreme Court.
- ▪A federal appeals court ruled that mifepristone must be distributed in person at clinics, not by mail.
- ▪The decision stems from Louisiana's challenge, arguing that mail delivery undermines its total abortion ban.
- ▪Since the overturning of Roe v. Wade, abortion numbers in the U.S. have slightly increased due to telehealth access to mifepristone and misoprostol.
Opening excerpt (first ~120 words) tap to expand
NewsletterMorning Rounds Federal court blocks mailing of mifepristone Longevity “blue zones,” an update on uterine transplant science, and more Morning Rounds health news Manage alerts for this article Email this article Share this article Charlie Neibergall/AP By Theresa GaffneyMay 4, 2026 Morning Rounds Writer and Reporter Theresa Gaffney[email protected]Theresa Gaffney is the lead Morning Rounds writer and reports on health care, new research, and public policy, with a particular interest in mental health, gender-affirming care, and LGBTQ+ patient communities. You can reach Theresa on Signal at theresagaff.97. Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning and happy Monday.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT.
Discussion
0 commentsMore from STAT
